Chimovits Erez reported conversion involving 256,448 shares of ADARx Pharmaceuticals, Inc. on Sep 28, 2026

Conversion
Form 4 code C. Conversion of a derivative security.
Director
DIR
Filed Sep 30, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
256,448Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
9,230,509Indirect · See footnotes
Trade date
Sep 28, 2026Conversion
Filed
Sep 30, 2026, 5:29 PM ET2-day reporting delay
Accession
0000947871-26-000912Code C · Transaction 232098
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 28, 2026Conversion1,333,975$0.00$0Trade 232101
Sep 28, 2026Conversion513,067$0.00$0Trade 232102
Sep 28, 2026Buy61,516$17.00$1,045,772Trade 232099
Sep 28, 2026Conversion7,127,019$0.00$0Trade 232100
Sep 28, 2026Conversion256,448$0.00$0Trade 232103
Sep 28, 2026Conversion7,127,019——Trade 232095
Sep 28, 2026Conversion1,333,975——Trade 232096
Sep 28, 2026Conversion513,067——Trade 232097
9 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

ADRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ADRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −13%30d −15%90d180d1y

Footnotes in full

F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date. F2: Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering. F3: These securities are held directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II. OrbiMed Advisors Israel II Limited ("Advisors Israel") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II. F4: Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.